Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform.
Ontology highlight
ABSTRACT: The multiplexed cancer cell line screening platform PRISM demonstrated its utility in testing hundreds of cell lines in a single run, possessing the potential to speed up anti-cancer drug discovery, validation and optimization. Here we described the development and implementation of a next-generation PRISM platform combining Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated gene editing, cell line DNA barcoding and next-generation sequencing to enable genetic and/or pharmacological assessment of target addiction in hundreds of cell lines simultaneously. Both compound and CRISPR-knockout PRISM screens well recapitulated the results from individual assays and showed high consistency with a public database.
SUBMITTER: Xia Y
PROVIDER: S-EPMC8253734 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA